Refeyn, a leading Life Science instrumentation company pioneering mass photometry, announced today that Gerry Mackay has been appointed the new CEO of the company effective January 1st, 2024.
Over the Q4 2023 period, Gerry will transition into his new role working with Jonathan Flint, Executive Chairman and the Leadership Team at Refeyn. Gerry brings extensive experience in Life Science as CEO of BioOutsource from 2009 to 2015, various senior roles in Commercial and General Management at Millipore and most recently as a member of Sartorius AG’s Executive Board and Head of the Lab Products Division until 2023.
Gerry has a Bachelor of Sciences degree in Biochemistry and a Master’s degree in Education from the University of Glasgow. Jonathan Flint, Executive Chairman of Refeyn said: “I am delighted that Gerry is joining us. His experience and capability are an excellent fit for Refeyn. I look forward to working with him in the next stage of Refeyn’s growth. I would also like to thank the team at Refeyn for their excellent work this year whilst we completed our CEO search.”
Gerry Mackay, the incoming CEO said: “In a very short amount of time, Refeyn’s mass photometry portfolio has proven its disruptive potential for various bioanalytical workflows. I am excited to now join the journey – helping our customers by simplifying research, accelerating process development and ultimately monitoring product quality in-line.”